GNI Group (2160) AI Stock Analysis

• Market Cap: €147.29B
• Dividend Yield: N/A
• Average Volume (3M): 1.54M
• Price to Earnings (P/E): 108.8
• Beta (1Y): 1.43
• Revenue Growth: -17.18%
• EPS Growth: -108.99%
• Country: JP
• Employees: 867
• Sector: Healthcare
• Sector Strength: 37
• Industry: Biotechnology
• EPS (TTM): -10.57
• Shares Outstanding: 50,564,545
• 10 Day Avg. Volume: 2,101,610
• 30 Day Avg. Volume: 1,540,926
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €3,605.57
• Price Target Upside: 19.99% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 49 Neutral
• Price Target: ¥2,990.00 ▼(-0.50% Downside)

The overall stock score is primarily influenced by the mixed financial performance, with a strong balance sheet but weak income and cash flow. Technical analysis suggests consolidation with bearish momentum, and valuation metrics indicate potential overvaluation due to negative earnings. The absence of earnings call data and corporate events limits additional insights.

GNI Group Business Overview & Revenue Model

Company Description

GNI Group Ltd, operating under the stock code 2160, is a biopharmaceutical company primarily engaged in the research, development, and commercialization of pharmaceutical products. The company focuses on treatments for inflammatory and fibrotic diseases, leveraging its proprietary technology platforms. With a strong presence in both Japan and China, GNI Group aims to address unmet medical needs through innovative therapeutic solutions.

How the Company Makes Money

GNI Group generates revenue through the development and sale of pharmaceutical products, particularly in the areas of inflammatory and fibrotic diseases. The company earns money from the commercialization of its proprietary drugs, which are distributed across various markets. Key revenue streams include sales of its flagship products and potential royalties or licensing fees from partnerships with other pharmaceutical companies. Additionally, the company may engage in collaborations or joint ventures to enhance its research capabilities and expand its market reach, contributing to its earnings.

GNI Group Financial Statement Overview

Summary

GNI Group shows a mixed financial picture with a strong balance sheet offset by weak income and cash flow statements. While the company maintains a stable equity position, declining revenues and negative earnings signal operational issues.

Income Statement

The company experienced a significant decline in performance with negative EBIT and net income in the TTM period. Gross profit margin remains strong, but revenue has decreased, indicating potential challenges in maintaining growth.

Balance Sheet

The balance sheet shows a solid equity base with an equity ratio of approximately 50%. The debt-to-equity ratio remains low, demonstrating a conservative leverage approach. However, the decrease in stockholders' equity may be concerning.

Cash Flow

Negative operating and free cash flows highlight liquidity challenges. The cash flow to net income ratio is unfavorable, indicating financial struggles in maintaining cash reserves.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	23.61B	26.01B	17.42B	12.69B	9.77B
Gross Profit	18.04B	22.43B	14.74B	11.09B	8.23B
EBITDA	2.39B	14.49B	2.16B	2.14B	2.19B
Net Income	977.66M	8.09B	-868.25M	55.24M	1.26B
Balance Sheet
Total Assets	71.94B	62.39B	33.91B	30.30B	23.22B
Cash, Cash Equivalents and Short-Term Investments	10.12B	23.15B	11.25B	14.36B	10.34B
Total Debt	7.21B	3.70B	537.36M	1.13B	1.75B
Total Liabilities	32.07B	26.34B	14.10B	11.03B	10.45B
Stockholders Equity	36.45B	33.79B	20.97B	18.86B	11.00B
Cash Flow
Free Cash Flow	-3.69B	4.47B	-1.55B	-142.13M	1.02B
Operating Cash Flow	-3.16B	6.55B	393.32M	552.27M	1.38B
Investing Cash Flow	-10.36B	-6.84B	-4.12B	-260.64M	570.21M
Financing Cash Flow	694.16M	10.69B	-646.33M	2.85B	801.12M

GNI Group Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 3005.00
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:2160, the sentiment is Positive. The current price of 3005 is above the 20-day moving average (MA) of 2946.95, below the 50-day MA of 3374.08, and above the 200-day MA of 2989.10, indicating a neutral trend. The MACD of -100.34 indicates Negative momentum. The RSI at 49.02 is Neutral, neither overbought nor oversold. The STOCH value of 77.13 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:2160.

GNI Group Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4587	76 Outperform	$217.59B	14.74	-9.08%	―	66.89%	506.88%
Sector *	65 Neutral	¥342.43B	8.69	-3.93%	2.47%	11.18%	-19.47%
4974	60 Neutral	¥110.42B	106.07		1.86%	3.53%	-29.66%
4593	54 Neutral	¥70.27B	―		―	374.19%	35.53%
2160	49 Neutral	€147.29B	108.76	-2.52%	―	-17.18%	-108.99%
4592	48 Neutral	¥176.08B	―	-197.82%	―	―	-3.32%
4565	45 Neutral	$85.25B	―	-3.36%	―	87.83%	75.84%

GNI Group Corporate Events

GNI Group Increases Stake in Gyre Pharmaceuticals to Boost Corporate Value

GNI Group Ltd. announced that its subsidiary, Gyre Therapeutics, has acquired additional shares in Gyre Pharmaceuticals, increasing its equity interest to 69.72%. This strategic move aims to minimize profit outflows to minority shareholders and enhance the Group’s corporate value, particularly as Gyre Pharmaceuticals is set to handle the entire value chain for a new liver fibrosis drug candidate. The acquisition is expected to positively impact the Group’s financial results, although the exact effect is still under review.

The most recent analyst rating on (JP:2160) stock is a Buy with a Yen3700.00 price target. To see the full list of analyst forecasts on GNI Group stock, see the JP:2160 Stock Forecast page.

GNI Group’s Cullgen Nears Nasdaq Listing After Shareholder Approval

GNI Group Ltd. announced that all agenda items related to the reverse merger between its subsidiary Cullgen Inc. and Pulmatrix, Inc. have been approved by Pulmatrix’s shareholders. This approval fulfills a key condition for Cullgen’s listing on the Nasdaq market, with only the China Securities Regulatory Commission’s approval pending. If the listing is delayed, the deconsolidation and recognition of a one-time gain will shift to the third quarter of 2025 or later, but the impact on GNI Group’s earnings forecast is expected to be limited.

The most recent analyst rating on (JP:2160) stock is a Buy with a Yen3700.00 price target. To see the full list of analyst forecasts on GNI Group stock, see the JP:2160 Stock Forecast page.

GNI Group’s Gyre Therapeutics Begins Phase 1 Trial for PAH Drug in China

GNI Group’s subsidiary, Gyre Therapeutics, has initiated a Phase 1 clinical trial in China for F230, a treatment candidate for pulmonary arterial hypertension (PAH). This marks the company’s entry into the PAH market, a rare and life-threatening condition with limited treatment options. The trial aims to assess the safety and pharmacokinetics of F230, a selective endothelin A receptor antagonist, and is part of Gyre’s strategy to expand its fibrosis treatment pipeline. The development is not expected to impact the company’s earnings forecast for the current fiscal year.

The most recent analyst rating on (JP:2160) stock is a Buy with a Yen3700.00 price target. To see the full list of analyst forecasts on GNI Group stock, see the JP:2160 Stock Forecast page.

GNI Group’s Gyre Pharmaceuticals Launches Etorel for Pulmonary Fibrosis

GNI Group’s subsidiary, Gyre Pharmaceuticals, has launched Etorel (Nintedanib Esilate Soft Capsules), marking a strategic advancement in the treatment of pulmonary fibrosis. This launch strengthens Gyre Pharmaceuticals’ position as a global leader in this field, addressing significant unmet clinical needs and expanding its market presence.

The most recent analyst rating on (JP:2160) stock is a Buy with a Yen3700.00 price target. To see the full list of analyst forecasts on GNI Group stock, see the JP:2160 Stock Forecast page.

GNI Group’s Subsidiary Gyre Therapeutics Completes Successful Public Offering

GNI Group Ltd. has announced the successful completion of a public offering by its subsidiary, Gyre Therapeutics, raising approximately $23 million. The proceeds will be used for research and development, manufacturing, and general corporate purposes. This offering slightly reduces GNI’s ownership in Gyre from 83.03% to 80.69%, but Gyre remains a consolidated subsidiary, ensuring no change in the scope of consolidation.

The most recent analyst rating on (JP:2160) stock is a Buy with a Yen3700.00 price target. To see the full list of analyst forecasts on GNI Group stock, see the JP:2160 Stock Forecast page.

GNI Group’s Liver Fibrosis Drug Achieves Key Trial Success in China

GNI Group Ltd.’s subsidiary, Gyre Therapeutics, has successfully completed a Phase 3 clinical trial in China for their liver fibrosis treatment drug, F351. The trial’s success, demonstrating significant fibrosis regression, positions the company favorably in the Chinese market for chronic hepatitis B-related liver fibrosis treatments.

The most recent analyst rating on (JP:2160) stock is a Buy with a Yen3700.00 price target. To see the full list of analyst forecasts on GNI Group stock, see the JP:2160 Stock Forecast page.

Gyre Therapeutics Launches $20 Million Public Stock Offering

Gyre Therapeutics, a subsidiary of GNI Group Ltd., has announced a public offering of its common stock, aiming to raise approximately $20 million. The proceeds will support the Phase 2 clinical trial of F351 in the U.S. and other corporate purposes, with a potential dilution rate of 2.83% for existing shareholders.

The most recent analyst rating on (JP:2160) stock is a Buy with a Yen3700.00 price target. To see the full list of analyst forecasts on GNI Group stock, see the JP:2160 Stock Forecast page.

GNI Group Reports Decline in Q1 FY2025 Financial Results

GNI Group Ltd. reported a decrease in revenue and profits for Q1 FY2025 compared to the same period last year, with revenue dropping by 10.6% and a significant decline in profits. The financial results indicate challenges in the company’s operations, impacting its market position and potentially affecting stakeholder confidence.

The most recent analyst rating on (JP:2160) stock is a Buy with a Yen3700.00 price target. To see the full list of analyst forecasts on GNI Group stock, see the JP:2160 Stock Forecast page.